Background: Laparoscopic right hemicolectomy (RHC) is the primary surgical approach for right-sided colon cancer. Different ileo-colonic anastomosis techniques may lead to varied postoperative outcomes. This study aims to compare intracorporeal versus extracorporeal side-to-side anastomosis post laparoscopic RHC for short-term outcomes in right-sided colon cancer patients.
Methods: This prospective, multicenter, cohort study utilized 1:1 propensity score matching (PSM) and inverse propensity of treatment weighting (IPTW) to address baseline imbalances. The primary endpoint was the incidence of anastomotic leakage (AL) within 30 days postoperatively, with its definition, diagnosis, and grading criteria standardized according to a published study.
Results: A total of 1028 eligible patients were analyzed, with 316 in the intracorporeal anastomosis (IA) group and 712 in the extracorporeal anastomosis (EA) group. After both PSM and IPTW, all 17 covariates were balanced between groups. No statistically significant difference in AL incidence was found between the two groups (before matching, 1.8% in EA and 1.6% in IA, P = 0.78; PSM, 1.3% in EA and 1.6% in IA, P = 0.74; IPTW, 1.9% in EA and 1.6% in IA, P = 0.76). However, peak C-reactive protein levels within 3 days postoperatively were higher in the EA group (before matching, P < 0.001; PSM, P < 0.001; IPTW, P = 0.003). Patients in the IA group had earlier postoperative defecation (before matching, P = 0.01; PSM, P < 0.001) and a shorter total hospital stay (before matching, P = 0.01; IPTW, P = 0.046). Post-PSM analysis showed earlier flatus in the IA group (P = 0.03), while post-IPTW analysis indicated later postoperative eating resumption in the IA group (P = 0.046).
Conclusions: Intracorporeal anastomosis during laparoscopic RHC for right-sided colon cancer does not increase the incidence of AL or other short-term complications. Furthermore, it facilitates postoperative bowel function recovery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00464-025-11592-w | DOI Listing |
J Biomater Appl
March 2025
Department of Chemistry, School of Pharmacy, North Sichuan Medical College, Nanchong, China.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. Capecitabine is a chemotherapeutic agent commonly used for the treatment of colon cancer. To realize local sustained release, promote efficient local intracellular transport, and mitigate the systemic toxic effects of capecitabine, a capecitabine prodrug, capecitabine-poly (p-dioxanone) (Cap-PPDO), was successfully synthesized.
View Article and Find Full Text PDFInt J Cancer
March 2025
Center for Epigenetics & Disease Prevention, Texas A&M HEALTH, and Department of Translational Medical Sciences, Texas A&M University Naresh K. Vashisht College of Medicine, Houston, Texas, USA.
A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.
View Article and Find Full Text PDFAltern Ther Health Med
March 2024
Background: Hospice palliative care is used as a last resort to relieve the clinical symptoms of elderly colon cancer patients. The nurse is a key participant in the overall care process. However, little is known about hospice palliative care from a nursing perspective.
View Article and Find Full Text PDFDis Colon Rectum
March 2025
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio.
Dis Colon Rectum
March 2025
Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Background: The extent of neoadjuvant therapy response, prior to surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!